Electrophoretic characterization of species of fibronectin bearing sequences from the N-terminal heparin-binding domain in synovial fluid samples from patients with osteoarthritis and rheumatoid arthritis by Peters, John H et al.
Introduction
Fibronectins (FNs), a family of multifunctional adhesion
proteins that differ from one another through alternative
splicing of a pre-mRNA derived from a single gene, are
found as soluble dimeric molecules in the blood and as
insoluble multimers within the extracellular matrix of
tissues, where they are concentrated in basement
membranes and blood vessel walls [1–3]. They bind to
cell-surface integrin receptors and participate in a variety
of cellular processes, including adhesion, migration,
1D = one-dimensional; 2D = two-dimensional; BSA = bovine serum albumin; CBD = cell-binding domain; CHAPS = 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate; ECL = enhanced chemiluminescence; FN = fibronectin; FT = flow-through; GBD =
gelatin-binding domain; HBD = heparin-binding domain; HRP = horseradish peroxidase; mAb = monoclonal antibody; OA = osteoarthritis; PBS =
phosphate-buffered saline; pFN = plasma-derived fibronectin; PMSF = phenylmethylsulfonyl fluoride; RA = rheumatoid arthritis; SD = standard devi-
ation; SF = synovial fluid; TBST = triethanolamine-buffered saline plus 0.05% Tween 20; Tris = tris(hydroxymethyl)aminomethane.
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Abstract
Fragments of fibronectin (FN) corresponding to the N-terminal
heparin-binding domain have been observed to promote
catabolic chondrocytic gene expression and chondrolysis. We
therefore characterized FN species that include sequences
from this domain in samples of arthritic synovial fluid using one-
and two-dimensional (1D and 2D) Western blot analysis. We
detected similar assortments of species, ranging from ~47 to
greater than 200kDa, in samples obtained from patients with
osteoarthritis (n=9) versus rheumatoid arthritis (n=10). One
of the predominant forms, with an apparent molecular weight of
~170kDa, typically resolved in 2D electrophoresis into a
cluster of subspecies. These exhibited reduced binding to
gelatin in comparison with a more prevalent species of
~200+kDa and were also recognized by a monoclonal
antibody to the central cell-binding domain (CBD). When
considered together with our previous analyses of synovial fluid
FN species containing the alternatively spliced EIIIA segment,
these observations indicate that the ~170-kDa species
includes sequences from four FN domains that have previously,
in isolation, been observed to promote catabolic responses by
chondrocytes in vitro: the N-terminal heparin-binding domain,
the gelatin-binding domain, the central CBD, and the EIIIA
segment. The ~170-kDa N-terminal species of FN may
therefore be both a participant in joint destructive processes
and a biomarker with which to gauge activity of the arthritic
process.
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transformation, and apoptosis, as well as wound healing,
fibrosis, and hemostasis [1–5]. FN is deposited in carti-
lage from osteoarthritis (OA) [3,6–9], and fragmented
forms of FN have been detected in synovial fluid (SF) and
articular cartilage from patients with OA and patients with
rheumatoid arthritis (RA) [10–17]. On the basis of such
findings, plasma-derived FN (pFN) and specific purified
pFN fragments have been tested for their capacity to regu-
late the function of chondrocytes in vitro. Whereas intact,
soluble pFN has been observed to exert little or no effect,
several purified, proteolytically derived pFN fragments
have proved to be active [18–26]. Additionally, mixtures of
fragments derived from OA cartilage have been observed
to promote chondrolysis in vitro [17].
Although fragments corresponding to the 29-kDa (also
referred to as 30-kDa) amino-terminal (N-terminal) heparin-
binding domain (HBD) have been studied most exten-
sively, species derived from sites spanning most of the FN
molecule have been observed to trigger catabolic gene
expression in chondrocytes [18–26]. For example, purified
fragments of pFN corresponding to the 120- to 140-kDa
central cell-binding domain (CBD), the 50-kDa gelatin-
binding domain (GBD), and the 40-kDa C-terminal HBD
have each been observed to trigger release of proteogly-
cans from cartilage slices in vitro, as has a recombinant
version of the alternatively spliced EIIIA segment (Fig.1)
[18,22,25–27]. In addition, the 29-kDa N-terminal HBD
has been observed to trigger gene expression for
stromelysin, inducible nitric oxide synthetase, hyaluronan
receptor proteins, and other biologically active molecules
in cultured chondrocytes [20,21,23–26]. Chondrolysis
triggered by FN fragments occurs in association with local
release of catabolic cytokines, including tumor necrosis
factor α, interleukin-1β, and interleukin-1α [21]. Further-
more, intra-articular injection of either N-terminal or central
CBD fragments into rabbit joints triggers loss of cartilage
proteoglycan, whereas injection of intact, dimeric pFN
does not [28,29].
Our goal in this study was to characterize and compare
the assortments of N-terminal SF FN species in samples
from OA versus RA patients with respect to their domain
structures and ligand-binding properties. We have found
that, among the two predominant species of SF FN that
bear sequences from the N-terminal HBD in patients with
OA or RA, the smaller, ~170-kDa species binds less
readily to gelatin and to a monoclonal antibody (mAb) spe-
cific for the GBD than does the larger, ~200+-kDa
species. Furthermore, 2D electrophoretic analysis reveals
the ~170-kDa species to be comprised of distinct sub-
species, most of which extend sufficiently toward the
carboxy terminus (C terminus) to include the 10th type III
repeat within the central CBD. In addition to prominent
~200+- and ~170-kDa species, several additional forms
of FN that bear sequences from the N-terminal HBD were
detected in OA and RA samples. Each of the soluble
species identified in this study, in addition to its possible
roles in the promotion of arthritic joint injury, is a candidate
as a biomarker for the arthritic disease process.
Materials and methods
Synovial fluid samples
This research was conducted according to the principles
of the Declaration of Helsinki and was approved by com-
mittees overseeing human experimentation at the relevant
institutions. After informed consent had been obtained, SF
was taken from patients with OA or active RA who were
undergoing diagnostic and/or therapeutic arthrocentesis
at Long Island Jewish Medical Center, New Hyde Park,
NY, or at Winthrop-University Hospital, Minneola, NY,
USA. Fluid was drawn into plastic syringes and placed
directly into tubes containing EDTA, phenylmethylsulfonyl
fluoride (PMSF), and aprotinin at final concentrations
5.7mM, 1mM, and 500U/ml, respectively (Sigma Chemi-
cal Co, St Louis, MO, USA). The fluids were centrifuged at
500g, and supernatants were frozen at –80°C with the
exception of short periods at –20°C. The 9 OA samples
(numbered 1–9) and 10 RA samples (numbered 10–19)
that were analyzed in this study were previously examined
for their content of species of FN bearing the alternatively
spliced EIIIA segment [15].
Antibodies and purified FN fragments
Purified anti-FN mAbs specific for the N-terminal HBD
(mAb 1936) (hereafter referred to as anti-N-terminal mAb)
[1–3,30] and the GBD (mAb 1892) were from Chemicon
(Temecula, CA, USA) (Fig.1). mAb A2C2, which recog-
nizes the 10th type III repeat of FN [31], was a gift (as
ascites) from Dr Richard Hynes, Massachusetts Institute
of Technology, Cambridge, MA, USA. Purified proteolytic
fragments from human pFN corresponding to the 30-kDa
(equivalent to 29-kDa) N-terminal HBD, and a 45-kDa
stretch from the GBD (Fig.1), were from Sigma.
Affinity isolation of synovial fluid FNs using
immobilized gelatin
To block nonspecific binding sites, 25µl of
gelatin–Sepharose (Amersham Pharmacia, Piskataway,
NJ, USA) was rocked with 400µl 1% bovine serum
albumin (RIA grade, Sigma) in phosphate-buffered saline
(PBS) for 30 min at room temperature. SF (50µl ) plus 1%
BSA/PBS (225µl) were then added to individual bead
pellets, followed by PMSF, aprotinin, leupeptin, and EDTA,
to give final concentrations of 2mM, 9.9U/ml, 13.3µg/ml,
and 4mM, respectively. After rocking for 2h, supernatant
(‘flow-through’ [FT]) fractions were collected and bead
pellets were washed four times with PBS containing 2mM
EDTA. Gelatin beads were boiled in 40µl reduced sample
buffer (40mM Tris, pH6.8, containing 4.3% SDS, 21.5%
glycerol, 1mM EDTA, and 0.2M dithiothreitol) for 5 min
prior to SDS–PAGE [32].R331
Preparation from OA synovial fluid of a fraction
enriched in the ~170-kDa species
This fraction was prepared from OA SF sample 6 as
described, using sequential gelatin and heparin affinity
chromatography, step-gradient NaCl elution of ~170-kDa
N-terminal FN fragments from the heparin column, and
Centriprep (Amicon, Beverly, MA, USA) concentration of
the 250mM NaCl fraction [15].
Electrophoresis
One-dimensional (1D) and two-dimensional (2D) elec-
trophoresis was performed as described elsewhere [15].
Six volumes of FT, diluted six-fold during affinity isolation,
were submitted to 1D SDS–PAGE alongside one volume
of the corresponding SF. The weights of molecular stan-
dards (Gibco BRL, Rockville, MD, USA) are those
reported by the manufacturer for prestained proteins. For
2D analysis, 5µl of SF or FT obtained after affinity isolation
from SF was added to 100µl rehydration solution consist-
ing of 2% immobilized pH gradient buffer, 8M urea, and
2% CHAPS. Dithiothreitol (18.2mM), PMSF (2mM), and
aprotinin (0.1U/ml ) were added to the rehydration solu-
tion just before the sample, and the mixture was cen-
trifuged at 14,000g for 15 min and applied via sample
cup to a 7-cm isoelectric focusing strip (pre-equilibrated
overnight in rehydration solution) for focusing at 20°C in a
Multiphor II apparatus (Amersham Pharmacia) at 200V for
1 min followed by 3500V for 170 min. After storage at
–75°C, strips were incubated for 15 min in 50mM Tris,
pH 8.8, plus 6M urea, 30% glycerol, 2% SDS, trimmed to
exclude ~7mm from the anodic end, and submitted to 5%
SDS–PAGE with an overlay of 0.5% agarose in 25mM
Tris, 192mM glycine, and 0.1% SDS.
Western blot analysis
Proteins in 1D and 2D gels were electrophoretically trans-
ferred and stained as described elsewhere [15]. Nitrocel-
lulose membranes that had been blocked, stained with
primary antibodies, and washed with triethanolamine-
buffered saline plus 0.05% Tween 20 (TBST) were incu-
bated for 2 hours in TBST containing 125I-labeled donkey
Fab′ fragments specific for rabbit IgG, or whole rabbit IgG
specific for mouse IgG (Amersham Pharmacia) at 0.15 to
0.5µCi/ml; or horseradish peroxidase (HRP)-conjugated
affinity-purified goat anti-mouse IgG (Jackson ImmunoRe-
search, West Grove, PA, USA). Membranes that had been
incubated with iodinated antibodies were washed, dried,
and exposed to XAR film (Kodak, Rochester, NY, USA)
with an intensifying screen before development. Mem-
branes that had been exposed to HRP conjugates were
washed and overlaid with enhanced chemiluminescence
(ECL) reagent and then exposed to Hyperfilm ECL (Amer-
sham Pharmacia) for periods of 10s to 10 min before
development. Control membranes were stained with sec-
ondary antibodies only.
Quantitation, data presentation, and statistical analysis
Band densities were measured using a Phosphorimager
(Molecular Dynamics, Sunnyvale, CA, USA). Quantitative
data for OA versus RA samples is expressed as the
average±SD for each group. Statistical comparisons
between groups were made with Student’s t-test using
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Figure 1
Structure of fibronectin (FN), including recognition sites for the monoclonal anti-FN antibodies used in this study. The structure of an intact FN
subunit is shown, with the approximate binding sites for the three anti-FN monoclonal antibodies used in this study denoted by brackets at the top
and binding specificities for various domains and structural motifs shown at the bottom. The primary FN sequence extends from the amino (N)
terminus (NH2, left) to the carboxy (C) terminus (COOH, right) and consists of repeating motifs designated type I, II, and III repeats. In addition to
the 10th (counting rightward from the N terminus) type III repeat, cell surface integrin-binding motifs (‘Cell’) have been localized to the alternatively
spliced EIIIA and V segments. The cysteine residues through which subunits are dimerized are depicted near the C terminus.Sigma Stat Version 2.0 statistical software. P values less
than 0.05 were considered significant.
Results
The ~170-kDa N-terminal species of synovial fluid FN
typically exhibits reduced affinity for gelatin in
comparison with the N-terminal ~200+-kDa species
Since the potential for a particular species of FN to regu-
late chondrocyte function may be related both to its
capacity to be recognized by cell-surface receptors and to
its ability to bind to other components of the extracellular
matrix, we wished to compare the capacities of the various
N-terminal species of SF FN to bind to gelatin (denatured
collagen). This was assessed by comparison of the
content of N-terminal species of FN in SF samples before
and after exposure to immobilized gelatin. As we reported
previously, 1D Western blot analysis of unprocessed SF
reveals two predominant species in most OA and RA
samples, possessing apparent molecular weights of
~200+ and ~170kDa [15]. Given the proximity of the
GBD to the N terminus (Fig.1) [1–3], both of these large
N-terminal species would be expected to include gelatin-
binding sequences. However, when samples of SF were
subjected to affinity isolation on gelatin beads, the
~200+-kDa species was routinely observed to bind more
readily than the ~170-kDa N-terminal species (Fig.2). For
example, in all nine OA samples, the ratio of staining inten-
sities for ~200+- to ~170-kDa bands decreased in the
gelatin-bead FT fraction in comparison with the starting
material (Fig.2, top panel). Furthermore, the average inten-
sity of the ~170-kDa band in the FT was 61.5±44.2% of
the corresponding value in the starting material for the
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Figure 2
~170-kDa N-terminal species of fibronectin (FN) in samples of synovial fluid (SF) from patients with osteoarthritis (OA) or rheumatoid arthritis (RA)
bind to gelatin less avidly than do larger species bearing sequences from the N-terminal heparin-binding domain. Samples of SF from patients with
OA (samples 1–3, 5, and 7–9 in the upper panels) or RA (samples 10–19 in the lower panels) were mixed with gelatin Sepharose beads, flow-
through fractions were collected, and the beads were washed and boiled in reduced sample buffer to elute bound FN species. SF starting material
(‘S’), flow-through fractions (‘F’), and bead eluates (‘E’) were then subjected to reduced 4–15% SDS–PAGE followed by Western blot analysis
using mAb 1936 specific for an epitope in the N-terminal heparin-binding domain, followed by iodinated secondary antibodies. With the exception
of RA SF samples 16 and 19, for which staining was restricted mainly to an ~200+-kDa band, the starting samples included two major species of
FN, migrating at ~200+ and ~170 kDa, respectively. Whereas the ~200+-kDa band was stained more intensely than the ~170-kDa band in most
samples, the flow-through fractions typically contained greater quantities of ~170- than ~200+-kDa species. Equivalent quantities of flow-through
fractions and starting material were subjected to electrophoresis, whereas the volume of gelatin eluate was equivalent to four times the volume of
starting material. OA samples 4 and 6 also exhibited lower ‘200+:170’ ratios in flow-through fractions than in the starting fractions (not shown).
The positions of molecular weight standards are denoted to the left of each panel, whereas the positions of the two predominant species of SF FN
(‘200+’ and ‘170’) are denoted by arrows to the left of the far left upper and lower panels only. The figure represents a composite derived from one
autoradiagram, which was exposed overnight.seven OA samples shown in Fig.2, whereas FT fractions
lacked visible staining for the ~200+-kDa species.
Similarly, although RA samples 16 and 19 lacked suffi-
cient staining of ~170-kDa forms to permit assessment,
the ratio of staining intensities for ~200+- to ~170-kDa
bands decreased in the FT fractions in comparison with
the starting material in the remaining eight RA samples,
with little or no staining for ~200+-kDa species in the FT
fractions (Fig.2, bottom). The average intensity of staining
of the ~170-kDa band in the FT fractions averaged
81.5±49.6% of the corresponding value in the starting
material for the eight RA samples in which two major
bands were detected by anti-N-terminal-HBD mAb
(excluding samples 16 and 19).
Reflecting the preferential gelatin-binding capacity of the
~200+-kDa species as opposed to that of the ~170-kDa
species of SF FN, gelatin isolates from both OA and RA
samples were uniformly enriched in the former as com-
pared with the latter species. In addition to ~200+-kDa
forms, fragments smaller than ~170 kDa were detected in
gelatin isolates derived from 6 of the 8 OA samples and 9
of the 10 RA samples shown in Fig.2. Specifically, gelatin-
binding N-terminal fragments with apparent molecular
weights of ~100, ~60, ~50, and ~47kDa were detected
in both OA and RA samples (Fig.2).
Similar to the staining pattern previously obtained on
these same samples with anti-total-FN antibody [15], anti-
N-terminal-HBD mAb was observed to produce preferen-
tial staining of the ~200+- as compared with the
~170-kDa species in both OA and RA SF samples. The
ratio of staining intensities for the ~200+-kDa bands as
compared with the ~170-kDa bands was significantly
greater in the 10 RA than in the 9 OA samples
(22.6±35.0 and 3.8±6.9, respectively; P<0.05).
Although the magnitude of this difference could largely be
attributed to RA samples 16 and 19, which exhibited neg-
ligible staining for the ~170-kDa species, the average
ratio for the remaining eight RA samples (6.2±3.4) was
also significantly greater than for the OA group (P<0.05).
Despite the use of gradient gels with the capacity to
resolve species as small as ~15kDa, little or no staining of
forms of FN smaller than ~170kDa was detected in
unconcentrated SF samples by anti-N-terminal-HBD mAb
(or anti-total-FN polyclonal antibody; not shown) after
autoradiogram exposure times of 5 days (Fig.2).
Analysis of species of synovial fluid FN bearing
sequences from the N-terminal HBD under nonreducing
conditions
Since FN exists in nature as dimers that are disulfide-
bonded near their C termini (Fig.1), information regarding
the state of such bonds is not forthcoming in reduced
electrophoretic analysis. When OA SF sample 6 was sub-
jected to nonreduced SDS–PAGE, species bearing an
N-terminal HBD sequence with migration expected of FN
dimers and monomers predominated, in addition to a
Available online http://arthritis-research.com/content/5/6/R329
R333
Figure 3
Nonreduced analysis of species of osteoarthritis (OA) synovial fluid
fibronectin (FN) that bear sequences from the N-terminal heparin-
binding domain. (a) OA sample 6 was subjected to gelatin affinity
isolation, and the starting material (‘SM’) and flow-through (‘FT’)
fractions were submitted to 5% nonreduced SDS–PAGE followed by
Western blot analysis in duplicate using monoclonal antibodies (mAbs)
specific for the N-terminal heparin-binding domain (‘anti-N-term’) or the
gelatin-binding domain (GBD) (mAb 1892, ‘anti-GBD’). In the starting
material and the flow-through fraction, the anti-N-terminal mAb
recognized a fragment species with mobility expected of a reduced
protein of ~140 kDa (‘F’), in addition to dimeric (‘D’) and monomeric
(‘M’) species. Although staining of all three species was less in the
flow-through fraction than in the starting material, the reduction in
staining of the dimeric and monomeric forms was substantially greater
than for the fragment species. In contrast, the anti-GBD mAb
produced staining of species with mobility expected of dimeric (‘D’)
and monomeric (‘M’) FNs but did not stain a fragment species in the
starting material or the flow-through fraction. The two pairs of lanes
were derived from one autoradiogram, which was exposed overnight.
Similar results, in which dimeric and monomeric species of FN were
stained by anti-GBD mAb to the exclusion of the smaller fragment
species, were obtained for OA samples 1, 4, and 9 (not shown). (b)
Purified 30-kDa N-terminal heparin-binding (’30 K’) and 45-kDa gelatin-
binding (’45 K’) fragments of human FN (2.5 µg each), as well as the
170-kDa-enriched fraction derived from OA synovial fluid sample 6
(‘170 K’) (5 µl) [15], were subjected to duplicate 4–15% nonreduced
SDS–PAGE and Western blot analysis using mAbs to the N-terminal
heparin-binding domain (left) or to the GBD (right). The anti-N-terminal
mAb produced staining of the 30-kDa fragment and a species with
migration expected of a reduced protein of ~140-kDa within the 170-
kDa-enriched fraction, but failed to stain the 45-kDa fragment. In
contrast, the anti-GBD mAb produced bright staining of the 45-kDa
fragment, but failed to stain the 30-kDa fragment or material in the
170-kDa-enriched fraction. The 30-kDa fragment migrated faster than
expected from the positions of migration of reduced molecular weight
standards shown to the left of each panel, possibly reflecting the effect
of maintenance of type I repeat intrachain disulfide bonds upon
conformation under nonreducing conditions. Autoradiagram exposure
times were 4 hours for the 30 K and 45 K lanes, and overnight for the
170 K lanes.major species that migrated at a position expected for a
reduced, ~140-kDa protein (Fig.3a). The latter species
appeared to equate with the ~170-kDa species seen in
reduced electrophoresis, since an ~140-kDa band also
predominated in the fraction enriched in the ~170-kDa
species derived from the same sample [15], whether
staining was achieved with anti-N-terminal-HBD or anti-
CBD mAbs (not shown).
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Figure 4
2D Western blot analysis of species of osteoarthritis (OA) synovial fluid fibronectin (FN) that contain sequences from the N-terminal heparin-
binding domain (HBD). Samples of OA synovial fluid (5 µl) were subjected to isoelectric focusing in linear pH gradients followed by reduced 5%
SDS–PAGE and Western blot transfer analysis, using anti-N-terminal-HBD mAb 1936 followed by iodinated secondary antibodies. Sample
numbers are shown in the right upper corner of each panel. Except for sample nine, blots resulting from pH 4–7 first-dimension isoelectric focusing
are presented. The pH 3–10 gradient used for sample nine (i) permitted detection of an ~130-kDa species which was also evident in the three
other samples (OA samples 3, 5, and 8) that were submitted to pH 3–10 gradients (not shown). A portion of each synovial fluid sample (5 µl) was
submitted to 1D electrophoresis in a lane at the left of each SDS–PAGE gel, and asterisks denote the approximate positions of migration of the
~200+- and ~170-kDa species in these lanes. At least part of the staining of material that migrated as a diffuse band at or near the dye-front in 1D
lanes appeared to be nonspecific, since similar staining was present in 1D Western blot analysis of unconcentrated synovial fluid samples in the
absence of primary mAbs (not shown). (a) Schematic diagram of the typical 2D migration of three predominant species of synovial fluid FN bearing
sequences from the N-terminal HBD: (1) ~170-kDa (major cluster denoted by brackets facing upward): Eight of the nine OA samples contained
between two and six ~170-kDa subspecies that migrated as a nearly horizontal array of spots in the cathodic half of the first dimension (pI ~6.0 to
~7.0). In sample number 2 (c), little or no such staining of a ~170-kDa species could be detected, and this correlated with an absence of staining
of this species in the 1D lane. Additional ~170-kDa material that migrated much closer to the anode (pI ~4.3) was detected in samples 4
(arrowhead pointing to the right) and 9 (not visible in the pH 3–10 blot in panel i). A species possessing an apparent molecular weight slightly
greater than 170-kDa (~180-kDa) was detected as a small spot beneath the cathodic aspect of the ~200+ kDa cluster in samples 1, 3, 4, 7, and 8
(diagonal arrows pointing upward and to the left). (2) ~185-kDa (denoted by small brackets facing downward): OA samples 1 and 3 (b,d), and 5
and 9 (f,g) (blots/exposures not shown) contained an additional fragment species, comprising between one and four faint spots. Similar to the
~170-kDa species, these forms migrated as a near-horizontal array of spots, but farther toward the anode and more slowly (Table 1). (3) ~200+
kDa (denoted by large brackets facing downward): This was detected in all OA samples tested, typically as a large and poorly defined cluster that
migrated in the right upper quadrant of each blot. Additional material of ~200+ kDa that migrated farther toward the anode than the major ‘cluster’
is evident in samples 2, 4, 5 and 9 (c,e,f,i) (short arrows pointing toward the right) (see Table 1). Autoradiogram exposure times were 5 days for
samples 1, 3, 5, and 8; 6 days for samples 2, 4, and 7; and 10 days for sample 9. A blot of OA sample 6 is not included in this figure, but can be
seen in Figure 6.SF was also analyzed under nonreducing conditions using
an anti-GBD mAb (mAb 1892), which does not recognize
FN under reducing conditions (manufacturer’s information
and unpublished observations, J Peters). In contrast to the
anti-N-terminal-HBD mAb, which stained a major fragment
species in addition to dimers and monomers, mAb 1892
produced staining of dimeric and monomeric species but
did not recognize a faster-migrating fragment species,
either in unprocessed SF or in gelatin FT (Fig.3a). The
failure of mAb 1892 to stain species of SF FN smaller
than monomers did not stem from an inability to recognize
the GBD in FN fragments, since this antibody retained the
capacity to produce specific staining of a 45-kDa GBD-
containing fragment (Fig.3b).
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Figure 5
2D Western blot analysis of species of rheumatoid arthritis (RA) synovial fluid fibronectin
(FN) that contain sequences from the N-terminal heparin-binding domain. RA synovial fluid
samples 10–19 were subjected to linear pH 4–7 first-dimension isoelectric focusing
followed by reduced second-dimension 5% SDS–PAGE. After transfer, membranes were
stained with mAb to the N-terminal heparin-binding domain followed by iodinated
secondary antibodies. Sample numbers are shown in the right upper corner of each panel.
Species of ~200+ kDa (large brackets facing down) that migrated at a position similar to
corresponding species in OA samples (see Fig. 4) were evident in all 10 RA samples. An
additional cluster of material of ~200+ kDa, denoted by short arrows pointing toward the
right, was evident in samples 11–13 and 15–19 (see Table 1). This material was streaked
upward in samples 12, 16, 17, and 18. Definitive staining of ~170-kDa species (large
brackets facing up) was evident in samples 10–15, 17, and 18. Additional ~170-kDa
material that migrated much closer to the anode (pI ~4.3) than the major cluster was evident in RA sample 17 (h) (arrowhead pointing toward the
right). An additional species that possessed a molecular weight of approximately 180 kDa was detected as a spot beneath the cathodic aspect of
the cluster of ~200+ kDa in samples 11–15 (diagonal arrows pointing upward and to the left) (see Table 1). An ~185-kDa species (small bracket
facing down) is evident in samples 10, 11, 13–15, and 18. Autoradiograms were exposed overnight for sample 19, 2 days for sample 18, 4 days
for samples 10, 13, and 16, 5 days for samples 11, 14, 15, and 17, and 6 days for sample 12. No definitive staining of ~170- or ~185-kDa
species was observed in samples 16 or 19, even after exposure times as long as 10 days.Analysis of species of synovial fluid FN bearing
sequences from the N-terminal HBD using two-
dimensional Western blot analysis
To provide greater electrophoretic resolution of N-terminal
species of SF FN, each SF sample was submitted to 2D
Western blot analysis using a pH 4–7 isoelectric focusing
gradient in the first dimension, followed by reduced 5%
SDS–PAGE in the second. Three major species of SF FN
were typically detected in samples from both types of
patient: a ~200+-kDa cluster of staining, corresponding to
the ~200+-kDa species in 1D electrophoresis; a series of
~170-kDa spots corresponding to the ~170-kDa band;
and a more faintly stained series of ~185-kDa spots
(Figs4 and 5; Table 1).
In SF samples from both patient groups, the ~200+-kDa
N-terminal species was typically detected as a cluster that
spanned a broad pI range (~4.9 to ~5.9) (Figs4 and 5;
Table 1). In 8 of 10 RA and 4 of 9 OA samples, a separate
cluster of ~200+-kDa staining could also be detected
migrating closer to the anode (pI~4.0 to ~4.4) than the
major cluster (Figs4 and 5; Table 1). This ‘extra’ material
Arthritis Research & Therapy    Vol 5 No 6 Peters et al.
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Table 1
Species of fibronectin bearing the N-terminal heparin-binding domain in samples of synovial fluid from patients with osteoarthritis
(OA) and rheumatoid arthritis (RA)a
Fibronectin species bearing N-terminal heparin-binding domain
~200+ kDa ~200+ kDa ~170 kDa ~170 kDa ~185 kDa ~180 kDa ~ 130 kDa
Synovial fluid sample pI ~4.9–5.9 pI ~4.0–4.4 pI ~6.0–7.0 pI ~4.3 pI ~5.8–6.4 pI ~5.5–5.8 pI ~9.1
From OA
1 +–+–++ N T
2 ++–––– N T
3 +–+–+++
4 ++++–+ N T
5 +++–+–+
6 +–+––– N T
7+ – + – – + N T
8 +–+–+++
9 ++++––+
+/totalb 9/9 4/9 8/9 2/9 4/9 5/9 4/4c
From RA
1 0 +–+–+– N T
1 1 +++–++ N T
1 2 +++––+ N T
1 3 +++–++ N T
1 4 +–+–++ N T
1 5 +++–++ N T
1 6 ++–––– N T
1 7 ++++–– N T
1 8 +++–+– N T
1 9 ++–––– N T
+/totalb 10/10 8/10 8/10 1/10 6/10 5/10 NT
aSamples of synovial fluid were subjected to two-dimensional electrophoresis in linear pH 4–7 isoelectric focusing gradients followed by reduced
5% SDS–PAGE and Western blot analysis using mAb 1936 specific for the N-terminal heparin-binding domain of fibronectin. OA samples 3, 5, 8
and 9 were additionally subjected to analysis using pH 3–10 linear first-dimension gradients, which permitted detection of a ~130-kDa N-terminal
species (rightmost column). bThe numerator is the number of samples in which a particular species of FN was detected (+) and the denominator is
the total number of samples tested. cFour OA samples and no RA samples were subjected to pH 3–10 gradients, which permitted detection of the
~130-kDa species. –, species not detected; NT, not tested.was streaked vertically upward in the second dimension in
four of eight RA (Fig.5) and two of four OA (Fig.4)
samples.
In most samples, the ~170-kDa species resolved into a
cluster of one to six spots arrayed nearly horizontally in the
second dimension, with pIs ranging from ~6.0 to ~7.0
(Figs4 and 5). In the two SF samples for which gelatin FT
fractions were submitted to 2D analysis (OA samples 1
and 3), these subspecies persisted in the absence of
~200+-kDa species (not shown). An additional ~170-kDa
spot that migrated farther toward the anode (pI~4.3) was
detected by anti-N-terminal mAb in two OA samples
(including sample 4 in Fig.4; Table 1) and one RA (sample
17 in Fig.5; Table 1) sample. Additionally, a spot that
migrated slightly more slowly in the second dimension
(~180kDa, pI~ 5.5–5.8) was detected in OA samples 1,
3, 4, 7, and 8, as well as RA samples 11–15 (denoted by
diagonal arrows pointing upward and to the left in Figs4
and 5; Table 1).
In 4 of the 9 OA samples (1 and 3 in Fig.4, also samples
5 and 9 in blots not shown; Table 1) and 6 of the 10 RA
samples (10, 11, 13–15, and 18 in Fig.5; Table 1), mAb
to the N-terminal HBD produced staining of an ~185-kDa
species that migrated slightly farther toward the anode
(pIs ranging from ~5.8 to ~6.4) than the ~170-kDa cluster
(Figs4 and 5). A faint band corresponding to this species
could also be detected in 1D Western blots subjected to
long autoradiographic exposures (not shown) [15]. Similar
to the ~170-kDa cluster, the ~185-kDa subspecies per-
sisted in the gelatin FT fraction from OA sample 1 (no
staining of an ~185-kDa species was evident in the
aliquot of OA sample 3 that was submitted to gelatin isola-
tion), despite the absence of ~200+-kDa species from
this fraction (not shown).
In addition to pH 4–7 gradients, OA samples 3, 5, 8, and
9 were analyzed using pH 3–10 first-dimension gradients.
In each case, a cluster of staining that migrated at
~130-kDa in the second dimension, and too close to the
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Figure 6
Sequences from the N-terminal heparin-binding domain and the 10th type III repeat reside together within common subspecies of ~170-kDa
synovial fluid fibronectin (FN) fragment. Aliquots of osteoarthritis (OA) sample number 6 (5 µl) were subjected to isoelectric focusing in duplicate
pH 4–7 first-dimension (1D) strips, each of which was then subjected to reduced 5% SDS–PAGE. A portion (5 µl) of the sample was also
submitted to reduced 1D PAGE in a lane at the edge of each of the two second-dimension gels. After incubation with anti-N-terminal heparin-
binding domain mAb followed by HRP-conjugated secondary antibodies, similar enhanced chemiluminescence (ECL) staining patterns were
obtained for the resulting two membranes (a, c) after a film development time of 1 minute. Specifically, two major bands were evident in the 1D
lane, representing ~200+ (upper arrow) and ~170-kDa (lower arrow) species. Additionally, three major ‘spots’ (denoted by three vertical arrows),
consistent with ~170-kDa species (brackets facing upward), were evident as a nearly horizontal array in the cathodic half of each membrane,
approximating the point of migration of the corresponding species within the 1D lane. A cluster of staining with migration approximating that of the
~200+ kDa band was also evident in each membrane (brackets facing downward). The membranes were stripped of antibodies for 30 min at
50°C in 6.25 mM Tris pH 6.7 containing 100 mM β-mercaptoethanol and 2% SDS, then washed in TBST and reblocked with blotto. One was
stained with mAb A2C2 diluted in blotto (panel B), whereas the other was incubated in blotto alone (panel D). After incubation with HRP-
conjugated secondary antibodies, both membranes were again subjected to ECL development and film exposure for 10 min. Staining was evident
in the membrane that had been incubated sequentially with anti-CBD mAb followed by secondary antibodies (b), but not in the membrane exposed
only to secondary antibodies (d). When the films shown in (a) and (b) were overlaid using membrane ‘edge staining’ as a guide, the three ~170-
kDa spots present in (a) were found to occupy indistinguishable spatial positions as compared with the corresponding spots evident in (b). In
comparison with the anti-N-terminal mAb, mAb A2C2 produced preferential staining of the ~200+ in comparison with the ~170-kDa species.anode (pI~9.1) to be evident in pH 4–7 gradients, was
detected (sample number 9, Fig.4i). Faintly stained
~130-kDa species were also detected in long exposures
of 1D blots from these four samples (Fig.1) [15].
Anti-N-terminal-HBD and anti-CBD antibodies
recognize the same ~170-kDa FN subspecies in 2D
Western blot analysis of OA and RA synovial fluid
samples
Anti-CBD and anti-N-terminal-HBD mAbs were observed
to stain the same ~170-kDa spots in 2D analysis of OA
sample number 6 (Fig.6). Additionally, each of the two
mAbs exhibited corecognition of ~170- and ~185-kDa
species in RA sample 18 (not shown).
Discussion
Despite dramatic clinical and pathologic differences
between the OA and RA, we have detected qualitatively
similar arrays of N-terminal species of FN in SF samples
from patients with the two disorders. Specifically, although
there was a greater preponderance of ~200+-kDa as
compared with ~170-kDa forms in RA versus OA
samples, generally similar assortments of such species,
ranging from ~47 to ~200+kDa, were detected in the two
types of sample both by 1D and 2D Western blot analysis.
Therefore, the similarity in 2D electrophoretic resolution
patterns that we previously reported for one patient with
OA and another with RA [15] appears to be more gener-
ally applicable.
2D Western blot analysis revealed that samples of SF
from OA and RA joints share in common at least six N-ter-
minal species of FN (Table 1). One of the most prevalent,
with a molecular weight of ~170 kDa, was found to usually
be comprised of subspecies which, by antibody mapping
in this and a previous study [15], appear to include
sequences from four domains that have previously, in the
context of small purified fragments or partial recombinant
FNs, proved to be potent in the regulation of chondrocyte
function, namely, the N-terminal HBD [18–20,23,24], the
GBD [18], the central CBD [18,19,20], and the alterna-
tively spliced EIIIA segment [27]. The ~170-kDa species
therefore appears structurally similar to a placenta-derived
FN fragment that was previously observed to trigger
expression of matrix metalloproteinase by synovial cells
[27].
Although the mechanisms by which FN fragments regulate
chondrocyte function remain uncertain [25,26], a close
physical interaction has been detected between central
cell-binding FN fragments and the α5 integrin subunit on
chondrocytes in vitro, suggesting that surface-expressed
integrins could constitute intermediaries in the transduc-
tion of catabolic signals from such fragments to chondro-
cytes [33]. Such signal transmission could also emanate
from sequences near the N terminus of FN, based upon
the observation that N-terminal fragments lacking central
CBD sequences are recognized by α5β1 integrins on
fibroblasts [34]. Although similar observations have not
yet been reported for chondrocytes, α5β1 integrins are
prevalent on the surfaces of chondrocytes in vivo and in
vitro [35,36]. Therefore, the ~170-kDa forms of FN
described in this study could potentially be recognized by
chondrocyte α5β1 integrins via sequences situated in both
the central CBD and the N-terminal HBD. Elucidation of
the primary sequence of all of the FN species detected in
this study will provide more clues to their functions.
Conclusion
Qualitatively similar assortments of FN species bearing
sequences from the N-terminal HBD are present in SF
samples from patients with OA and RA. One of the pre-
dominant species, possessing a molecular weight of
~170-kDa, is composed of distinct subspecies that have
lesser capacities for gelatin binding than larger N-terminal
species of SF FN. Since the ~170-kDa species has
central CBD sequences, yet exhibits reduced binding to
denatured collagen, it could potentially represent a soluble
agent with the capacity to disrupt FN-mediated interac-
tions between chondrocytes and their insoluble extracellu-
lar matrix. Based upon their potential roles in the
pathogenesis of arthritis, the species described in this
study also constitute candidate soluble biomarkers for the
joint-destructive process in OA and RA.
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